CORCEPT THERAPEUTICS INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
Mailing Address 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
Phone 650.688.8803
Fiscal Year End 1231
EIN 770487658
Financial Overview
FY2024
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 11, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 29, 2026 | View on SEC |
| 8-K Current report of material events | January 22, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 31, 2025 | View on SEC |
| 4 Insider stock transaction report | December 29, 2025 | View on SEC |
Material Events
8-K Other December 31, 2025
High Impact
- The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for CORCEPT THERAPEUTICS INC's new drug, relacorilant.
- Relacorilant was being considered as a treatment for patients with hypertension secondary to hypercortisolism.
Insider Trading
STRONG SELL 4 insiders
9 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.